On the other hand, compared to DPP-4 inhibitors and sulphonylureas, SGLT-2 inhibitors showed more advantages in preventing hospital admissions for heart failure and ≥40% decline in eGFR [122]. This evidence concerns the gene SLC5A2 and heart failure.